Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot, exploratory study is to evaluate the safety, tolerance,
pharmacokinetics and potential anti-inflammatory activity of an investigational agent,
HE3286, when administered orally for 29 days to patients with rheumatoid arthritis that are
taking a stable dose of methotrexate.